Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

被引:62
作者
Hirsch, FR [1 ]
Witta, S [1 ]
机构
[1] Univ Colorado, Ctr Canc, Dept Med Med Oncol & Pathol, Aurora, CO 80010 USA
关键词
epidermal growth factor receptor Inhibitors; fluorescence in situ hybridization; lung cancer; predictive markers;
D O I
10.1097/01.cco.0000155059.39733.9d
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review Epidermal growth factor receptor (EGFR) Inhibitors have shown promising results in patients with advanced non-small cell lung cancers (NSCLC) who previously have failed on chemotherapy. Objective response is achieved in 10 to 28% of the patients, and about 30% will achieve stable disease. A major problem is how to select the patients, who will benefit from treatment, and who will not. Recent findings The predictive role of EGFR protein expression assessed by IHC is still debated. Specific EGFR gene mutations have been identified associated with response to gefitinib (Iressa (R)), but seem not to be associated with stable disease. No studies have yet demonstrated any association between EGFR gene mutations and survival. In this review we describe other marker studies, which are associated with sensitivity to EGFR inhibitors. Increased EGFR gene copy number based on FISH analysis is demonstrated to be a good predictive marker for response, stable disease, time to progression, and survival. Summary EGFR/FISH seems today to be the best predictive i marker for clinical benefit from EGFR inhibitors in NSCLC. Prospective large scale clinical studies must identify the most optimal paradigm for selection of patients.
引用
收藏
页码:118 / 122
页数:5
相关论文
共 30 条
[1]   Can current treatments for advanced non-small-cell lung cancer be improved? [J].
Argiris, A ;
Schiller, JH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :499-500
[2]  
BAILEY LR, 2003, 94 ANN M AM ASS CANC
[3]   Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC [J].
Cappuzzo, F ;
Gregorc, V ;
Rossi, E ;
Cancellieri, A ;
Magrini, E ;
Paties, CT ;
Ceresoli, G ;
Lombardo, L ;
Bartolini, S ;
Calandri, C ;
De Rosa, M ;
Villa, E ;
Crinò, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2658-2663
[4]   Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J].
Cappuzzo, F ;
Magrini, E ;
Ceresoli, GL ;
Bartolini, S ;
Rossi, E ;
Ludovini, V ;
Gregorc, V ;
Ligorio, C ;
Cancellieri, A ;
Damiani, S ;
Spreafico, A ;
Paties, CT ;
Lombardo, L ;
Calandri, C ;
Bellezza, G ;
Tonato, M ;
Crinò, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1133-1141
[5]  
CAPPUZZO F, IN PRESS J NATL CANC
[6]  
Cappuzzo F, 2004, ANN ONCOL, V15, P166
[7]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[8]   Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer [J].
Han, SW ;
Hwang, PG ;
Chung, DH ;
Kim, DW ;
Im, SA ;
Kim, YT ;
Kim, TY ;
Heo, DS ;
Bang, YJ ;
Kim, NK .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (01) :109-115
[9]  
Hirsch FR, 2004, J CLIN ONCOL, V22, p623S
[10]   Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis [J].
Hirsch, FR ;
Varella-Garcia, M ;
Bunn, PA ;
Di Maria, MV ;
Veve, R ;
Bremnes, RM ;
Barón, AE ;
Zeng, C ;
Franklin, WA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3798-3807